Adagio Medical Holdings, Inc. (ADGM)
NASDAQ: ADGM · Real-Time Price · USD
1.075
+0.015 (1.42%)
Dec 27, 2024, 9:44 AM EST - Market open
Company Description
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias.
It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia.
The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories.
The company was founded in 2011 and is headquartered in Laguna Hills, California.
Adagio Medical Holdings, Inc.
Country | United States |
Founded | 2011 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 85 |
CEO | Todd Usen |
Contact Details
Address: 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 United States | |
Phone | 949-348-1188 |
Website | adagiomedical.com |
Stock Details
Ticker Symbol | ADGM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0002006986 |
ISIN Number | US00534B1008 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Olav B. Bergheim | Chairman and Chief Executive Officer |
John T. Dahldorf | Chief Financial Officer |
Hakon Bergheim | Chief Operating Officer |
Dr. Alex Babkin Ph.D. | Chief Technical Officer |
Nabil Jubran | Chief Compliance Officer |
Ilya Grigorov | Vice President of Global Marketing and Product Management |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 23, 2024 | 424B3 | Prospectus |
Dec 23, 2024 | 424B3 | Prospectus |
Dec 23, 2024 | 8-K | Current Report |
Dec 16, 2024 | 424B3 | Prospectus |
Dec 16, 2024 | 424B3 | Prospectus |
Dec 16, 2024 | 8-K | Current Report |
Nov 26, 2024 | 424B3 | Prospectus |
Nov 26, 2024 | 424B3 | Prospectus |
Nov 25, 2024 | EFFECT | Notice of Effectiveness |
Nov 25, 2024 | EFFECT | Notice of Effectiveness |